Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches.

New microbes and new infections·2026
Same author

Correction to: Chitosan‑embedded β‑cyclodextrin‑magnetic graphene oxide nanoparticles for curcumin loading: evaluating cytotoxicity and apoptosis induction in esophageal cancer.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Protocol Optimization for Exosome Production From Umbilical Cord Mesenchymal Stem Cells: A Step Toward Clinical Translation.

Basic and clinical neuroscience·2026
Same author

The Impact of Small Molecule on the Astrocyte's Viability Derived From Epileptic Brain Tissues.

Basic and clinical neuroscience·2026
Same author

Retraction Note: The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.

Molecular biology reports·2026
Same author

Apoptosis and Glial Marker Profiles in Hippocampus and Amygdala of Medically Intractable Temporal Lobe Epilepsy.

Journal of cellular and molecular medicine·2026

Related Experiment Video

Updated: Jun 21, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Development of Potential Inhibitors for Human T-lymphotropic Virus Type I Integrase Enzyme: A Molecular Modeling

Mohammad Jalili-Nik1,2, Arash Soltani1,3, Seyed Isaac Hashemy1,3

  • 1Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Current Computer-Aided Drug Design
|April 28, 2023
PubMed
Summary

Researchers identified novel drug-like compounds to inhibit Human T-lymphotropic Virus type I (HTLV-1) integrase, a key target for treating HTLV-1 infection. These potential inhibitors show promise for developing new antiviral therapies.

Keywords:
HTLV-1integraseintegrase inhibitorsligand-based designstructure-based designvirtual screening

More Related Videos

Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.6K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

Related Experiment Videos

Last Updated: Jun 21, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.6K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

Area of Science:

  • Virology
  • Medicinal Chemistry
  • Computational Biology

Background:

  • Human T-lymphotropic Virus type I (HTLV-1) integrase facilitates viral DNA integration into host genomes, making it a critical therapeutic target.
  • Despite its importance, no effective clinical inhibitors currently exist to combat HTLV-1 infection.

Purpose of the Study:

  • To identify novel, drug-like compounds with potent inhibitory activity against HTLV-1 integrase.
  • To explore structure-based drug design and virtual screening for discovering new antiviral agents.

Main Methods:

  • Utilized a structural model of HTLV-1 integrase and known inhibitors (dolutegravir, raltegravir, elvitegravir) for designing novel molecules.
  • Performed virtual screening against PubChem, ZINC15, and ChEMBL databases.
  • Assessed drug-likeness and binding affinity using SWISS-ADME and GOLD software, followed by molecular dynamics simulations for stability analysis.

Main Results:

  • Developed four novel potential inhibitors via structure-based design and identified three promising compounds from virtual screening.
  • Identified key hydrogen bonding interactions between inhibitors and critical HTLV-1 integrase residues (Asp69, Asp12, Tyr96, Tyr143, Gln146, Ile13, Glu105).
  • Observed π-stacking and halogen interactions with viral DNA, similar to parent molecules, and confirmed enhanced complex stability via molecular dynamics simulations.

Conclusions:

  • Combined structure-based design and virtual screening effectively identified potential HTLV-1 integrase inhibitors.
  • Three drug-like molecules (PubChem CID_138739497, _70381610, and _140084032) were identified as lead compounds.
  • These lead compounds offer a promising starting point for developing novel therapeutics against HTLV-1 infection.